Bicycle Therapeutics (BCYC) Gets a Buy Rating from Leerink Partners

In a report issued on March 1, Jonathan Chang from Leerink Partners maintained a Buy rating on Bicycle Therapeutics (BCYCResearch Report), with a price target of $70.00. The company’s shares closed last Wednesday at $46.92.

According to TipRanks.com, Chang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.5% and a 21.4% success rate. Chang covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Harpoon Therapeutics, and Mersana Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bicycle Therapeutics with a $69.29 average price target, representing a 46.9% upside. In a report issued on February 25, Needham also maintained a Buy rating on the stock with a $85.00 price target.

See the top stocks recommended by analysts >>

Based on Bicycle Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $4.33 million and GAAP net loss of $14.68 million. In comparison, last year the company earned revenue of $3.84 million and had a GAAP net loss of $10.14 million.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BCYC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Read More on BCYC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More